How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about capivasertib plus fulvestrant

Marketing authorisation indication

2.1

Capivasertib (Truqap, AstraZeneca) is indicated 'in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine based regimen'.

Price

2.3

Capivasertib costs £5,850 per 64-pack of 200-mg tablets (excluding VAT; company submission). Fulvestrant costs £55.32 for 2 pre-filled syringes of 250 mg/5 ml solution for injection (excluding VAT; drugs and pharmaceutical electronic market information tool [eMIT], accessed December 2024). The list price for 12 months of treatment is £77,088.12. The company has a commercial arrangement, which would have applied if capivasertib had been recommended.